Research To Practice | Oncology Videos

Latest Episodes:

HER2-Low Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast Cancer Jul 31, 2024

Show notes

Featuring an interview with Dr Kimberly H Allison, including the following topics:

Contemporary practices in pathology and reporting biomarkers of interest (0:00)
HER2 testing across numerous solid tumor types (2:47)
ER-low reporting category and pathologic interpretation (6:28)
PD-1/PD-L1 testing methodology and challenges with bone biopsies (10:53)

CME information and select publications

HER2-Low Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast Cancer (Companion Faculty Lecture) Jul 31, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Kimberly H Allison, including the following topics:

Pathological assessment of HER2 and appropriate testing methodologies (0:00)
Effect of the DESTINY-Breast04 study on clinical practice (12:32)
Relevancy of HER2-ultralow expression and implications of the DESTINY-Breast06 study (22:53)
Future directions in the pathological and clinical assessment of HER2-positive breast cancer (31:06)

CME information and select publications

Gynecologic Oncology | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology Jul 26, 2024

Show notes

Featuring perspectives from Dr Dana M Chase, including the following topics:

Introduction: ASCO 2024 Review (0:00)
Ovarian Cancer (14:29)
HER2 as a Therapeutic Target (29:18)
Endometrial Cancer (38:55)
Cervical Cancer (51:11)

CME information and select publications

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation Jul 25, 2024

Show notes

Featuring an interview with Dr Jonathan W Goldman, including the following topics:

Contemporary and Future Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00)
Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation (21:05)
Other Emerging Strategies for Relapsed Metastatic Lung Cancer (29:16)
Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation (37:59)
Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation (45:29)

CME information and select publications

Melanoma and Nonmelanoma Skin Cancers | Investigator Perspectives on Available Research and Challenging Questions in Melanoma and Nonmelanoma Skin Cancers: A Post-ASCO 2024 Annual Review Jul 19, 2024

Show notes

Featuring perspectives from Dr Nikhil I Khushalani and Dr Jason J Luke, including the following topics:

Introduction (0:00)
Evidence-Based Treatment of Nonmetastatic and Metastatic Melanoma — Dr Luke (2:49)
Optimizing the Management of Nonmelanoma Skin Cancers — Dr Khushalani (36:54)

CME information and select publications

Renal Cell Carcinoma | Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma: A Post-ASCO Annual Review Jul 18, 2024

Show notes

Featuring perspectives from Dr Rana R McKay and Prof Thomas Powles, including the following topics:

Introduction (0:00)
Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Prof Powles (12:39)
Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr McKay (49:27)

CME information and select publications

Colorectal Cancer | RTP Live from Chicago: Investigator Perspectives on Recent Advances and Challenging Questions in the Management of Colorectal Cancer Jul 16, 2024

Show notes

Featuring perspectives from Dr Scott Kopetz and Dr John Strickler, including the following topics:

Introduction (0:00)
Recent Therapeutic Advances in Colorectal Cancer (CRC) — Dr Strickler (1:53)
New Developments in Targeted Therapy for Metastatic CRC — Dr Kopetz (35:11)

CME information and select publications

Lymphoma | RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma Jul 12, 2024

Show notes

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, including the following topics:

Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00)
Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13)
Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-Cell Lymphomas — Dr Flinn (41:20)
Tolerability and Other Practical Considerations with the Use of Bispecific Antibody Therapy — Dr Brody(50:49)

CME information and select publications

Triple-Negative Breast Cancer | What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer Jul 11, 2024

Show notes

Featuring perspectives from Dr Kevin Kalinsky and Dr Heather McArthur, including the following topics:

Introduction (0:00)
Case: A woman in her mid 80s with a 2.7-cm residual tumor after neoadjuvant pembrolizumab/chemotherapy for localized triple-negative breast cancer (TNBC) — Ranju Gupta, MD (3:31)
Question and Comments: Approach to neoadjuvant therapy and defining residual disease; PD-L1 status and efficacy of pembrolizumab in the localized and metastatic settings — Kapisthalam (KS) Kumar, MD (8:04)
Case: A woman in her mid 60s with node-positive TNBC and a single lung metastasis who receives neoadjuvant therapy based on the KEYNOTE-522 trial — Dr Kumar (17:18)
Case: A woman in her early 70s with localized TNBC and residual disease after poorly tolerated neoadjuvant pembrolizumab/chemotherapy and lumpectomy — Dr Kumar (23:29)
Case: A woman in her late 60s with widely metastatic ER-negative, HER2-low disease after multiple lines of treatment — CDH1 and ERBB2-V697L mutations, microsatellite stable, tumor mutational burden 3 mut/Mb — Dr Gupta (29:13)
Question and Comments: Adjuvant therapy selection for patients with localized TNBC with a BRCA mutation and residual disease; risk of acute myeloid leukemia/myelodysplastic syndromes associated with PARP inhibitor therapy — Dr Kumar (40:52)
Case: A woman in her early 70s who develops recurrent metastatic ER-negative, HER2-low breast cancer after nab paclitaxel/atezolizumab and receives sacituzumab govitecan — Dr Gupta (46:49)

CME information and select publications

Multiple Myeloma | Breakfast with the Investigators: New Advances in Multiple Myeloma Jul 09, 2024

Show notes

Featuring perspectives from Dr Rafael Fonseca, Dr María-Victoria Mateos and Dr Elizabeth O'Donnell, moderated by Dr O'Donnell, including the following topics:

Introduction (0:00)
Treatment Approaches for Newly Diagnosed Multiple Myeloma (MM) — Dr Fonseca (2:05)
Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with MM — Dr Mateos (22:06)
Incorporation of Other Novel Agents and Strategies into the Management of Relapsed/Refractory MM — Dr O'Donnell (39:25)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected